4552 — JCR Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- ¥64bn
- ¥109bn
- ¥40bn
Brief: Medipal Recieves Orphan Drug Designation For JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results
Brief: JCR Pharmaceuticals Enters License Agreement With Alexion For Proprietary Just-Aav Capsids
Brief: Medipal Holdings Announces European Commission Granted Orphan Drug Designation To JR-446
Brief: JCR Pharmaceuticals - Chairman And President Transition As Of April 1, 2026
Table: Jcr Pharmaceuticals -2024/25 parent results
Table: Jcr Pharmaceuticals -2024/25 group results
Table: Jcr Pharmaceuticals -2024/25 group forecast
Table: Jcr Pharmaceuticals - 9-MTH group results
Brief: JCR Pharmaceuticals Initiates Phase III Clinical Trial Of JR-142 In Japan
To Buy Back Up To 2.98% Of Own Shares Via Tostnet-3 On Nov 1
Brief: Jcr Pharmaceuticals Presents Preclinical Gene Therapy Research At The European Society Of Gene And Cell Therapy 31St Annual Congress
Brief: JCR Pharmaceuticals Announces Completion Of Clinical Trial Notification Process In Japan For Phase I Study Of JR-441 For Mucopolysaccharidosis Type IIIA
Table: Jcr Pharmaceuticals -Q1 group results
Brief: JCR Pharmaceuticals Plans To Start Clinical Trial In Japan In First Half Of FY24
Table: Jcr Pharmaceuticals -2023/24 parent results
Table: Jcr Pharmaceuticals -2023/24 group results
Jcr Pharmaceuticals Regains Full Commercialization Rights To Jr-141
Table: Jcr Pharmaceuticals -2023/24 group results